Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis is a key immune checkpoint.
• Its dysfunction promotes tumor metastasis and immune evasion.
• Dysregulation of this pathway is implicated in various cancers.

Purpose of the Study:

• To elucidate the molecular mechanisms regulating PD-1/PD-L1 expression.
• To identify potential therapeutic targets for cancer treatment.
• To review current combination therapy strategies involving PD-1/PD-L1 inhibitors.

Main Methods:

• Review of signaling pathways including PI3K/Akt/mTOR and MAPK.
• Analysis of transcriptional factors (hypoxia-induced factors, PTEN, p53, CDK5, BRD4, STAT) involved in PD-1/PD-L1 regulation.
• Exploration of epigenetic and post-translational modifications affecting PD-1/PD-L1 levels.

Main Results:

• PI3K/Akt/mTOR and MAPK signaling pathways drive PD-1/PD-L1 expression and tumor progression.
• Multiple transcriptional factors modulate PD-1/PD-L1 expression.
• Epigenetic and post-translational mechanisms also regulate PD-1/PD-L1 levels.

Conclusions:

• Understanding the regulatory mechanisms of PD-1/PD-L1 provides novel therapeutic targets.
• Combination therapy with PD-1/PD-L1 monoclonal antibodies and small molecule inhibitors demonstrates significant clinical outcomes.
• Targeting the PD-1/PD-L1 axis offers a promising strategy for cancer immunotherapy.